Back HCV Treatment Experimental HCV Drugs

Experimental HCV Drugs

FDA Will Consider Approval of Daclatasvir for Genotype 3 Hepatitis C Treatment

The U.S. Food and Drug Administration (FDA) has accepted Bristol-Myers Squibb's application for approval of stand-alone daclatasvir (Daklinza) for the treatment of genotype 3 hepatitis C virus (HCV), to be used in combination with sofosbuvir (Sovaldi), the company announced last week.

alt

Read more:

Coverage of the 2015 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.

Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.

HIVandHepatitis.com coverage by topic

CROI website

3/2/15

alt

CROI 2015: Retrovirus Conference Starts Monday in Seattle

The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place next week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com will be on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).

alt

Read more:

CROI 2015: Retrovirus Conference Now Underway in Seattle

The 2015 Conference on Retroviruses and Opportunistic Infections (CROI) takes place this week, February 23-26, at the Washington State Convention Center in Seattle. CROI focuses on HIV treatment, prevention, and basic science. For the past several years it has also included substantial hepatitis C content, and this year will feature presentations on Ebola virus. HIVandHepatitis.com is on site in Seattle all week bringing you news coverage and Twitter updates (@HIVandHepatitis).

alt

Read more:

AbbVie Dual Regimen Highly Effective Against HCV Genotype 1b

A 2-drug combination consisting of AbbVie's ritonavir-boosted HCV protease inhibitor parataprevir and NS5A inhibitor ombitasvir -- part of the Viekira Pak regimen -- demonstrated a 95% cure rate for people with hepatitis C virus genotype 1b, the most common type in Japan, according to a recent company announcement.

alt

Read more: